证券代码：301111 证券简称：粤万年青 公告编号：2026-004 广东万年青制药股份有限公司 特此公告。 广东万年青制药股份有限公司 董事会 2026 年 1 月 30 日 1 附件：刘一鸣先生简历 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于近日收到保荐机构国 联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"）出具的《国联 民生证券承销保荐有限公司关于变更广东万年青制药股份有限公司持续督导保 荐代表人的函》。 国联民生承销保荐作为公司首次公开发行股票并在创业板上 市的保荐机构，原委派杜峰先生和陈雨先生担任公司持续督导保荐代表人，法定 持续督导期至 2024 年 12 月 31 日止。截至目前，持续督导期已届满，鉴于公司 募集资金尚未使用完毕，国联民生承销保荐对募集资金相关事项继续履行持续督 导职责。 现因陈雨先生工作变动，不再负责公司的持续督导保荐工作。为保证公司持 续督导工作的有序进行，国联民生承销保荐决定委派刘一鸣先生（简历详见附件） 接替陈雨先生担任公司 ...

证券之星消息，1月27日中药板块较上一交易日下跌1.42%，粤万年青领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002728 | 特一药业 | 13.84 | 4.93% | 150.12万 | | 20.51亿 | | 603139 | 康惠股份 | 24.09 | 1.82% | 5.34万 | | 1.26亿 | | 000538 | 云南白药 | 56.68 | 0.91% | 13.16万 | | 7.36 Z | | 600671 | 天目药业 | 19.11 | 0.31% | 1 5.09万 | | 9647.18万 | | 002198 | 嘉应制药 | 7.34 | 0.27% | 34.18万 | | 2.49亿 | | 000423 | 东阿阿胶 | 50.35 | -0.34% | 6.45万 | | 3.25亿 | | ...

Group 1 - The traditional Chinese medicine sector saw an increase of 0.9% on January 26, with Te Yi Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the traditional Chinese medicine sector showed significant price movements, with Te Yi Pharmaceutical rising by 10.01% to a closing price of 13.19 [1] Group 2 - The traditional Chinese medicine sector experienced a net inflow of 594 million yuan from institutional investors, while retail investors saw a net outflow of the same amount [2] - The top gainers included Te Yi Pharmaceutical, which had a net inflow of 286 million yuan, accounting for 37.60% of the total [3] - Conversely, major losers included Wei Kang Pharmaceutical, which fell by 8.50% to a closing price of 29.40, with a trading volume of 86,100 shares [2]

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has shown fluctuations in its financing activities and financial performance, indicating potential investment opportunities and risks [1][2]. Group 2 - As of January 22, Guangdong Wannianqing's stock price increased by 0.70%, with a trading volume of 141 million yuan. The financing buy-in amount was 10.76 million yuan, while the financing repayment was 11.04 million yuan, resulting in a net financing buy-in of -284,400 yuan [1]. - The total financing and securities balance for Guangdong Wannianqing reached 116 million yuan, accounting for 3.35% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in any short selling activities on January 22, with a short selling balance of 0 shares, indicating a lack of bearish sentiment in the market [1]. Group 3 - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period. The average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported an operating income of 228 million yuan, a slight decrease of 0.14% year-on-year. The net profit attributable to the parent company was -8.13 million yuan, representing a significant decline of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2].

Group 1 - The company expects a loss of 2.00 million to 4.00 million yuan in 2025, with a non-recurring loss of 15.00 million to 20.00 million yuan [1] - The primary reason for the performance change is that the newly expanded health consumer products and medical health business segments are still in the market cultivation phase, leading to high fixed cost allocation and a temporary impact on overall profits [1] - The estimated impact of non-recurring gains and losses on net profit during the reporting period is approximately 13.00 million to 16.00 million yuan [1]

格隆汇1月21日丨粤万年青(301111.SZ)公布，预计2025年亏损200.00万元–400.00万元，扣非亏损1,500.00 万元–2,000.00万元。本次业绩变动的主要原因系公司新拓展的健康消费品及医疗健康业务板块尚处于市 场培育期，相关业务收入尚未形成规模效应，导致固定成本分摊比例较高，从而对整体利润产生阶段性 影响。报告期内，公司预计非经常性损益对净利润的影响金额约为1,300-1,600万元。 ...

Core Viewpoint - The company expects a net profit loss attributable to shareholders of 2 to 4 million yuan in 2025, compared to a profit of 4.1627 million yuan in the same period last year [1] Group 1: Financial Performance - The primary reason for the performance change is that the newly expanded health consumer products and medical health business segments are still in the market cultivation phase, leading to high fixed cost allocation and a temporary impact on overall profits [1] - The company estimates that non-recurring gains and losses will impact net profit by approximately 13 to 16 million yuan during the reporting period [1]

证券代码：301111 证券简称：粤万年青 公告编号：2026-002 广东万年青制药股份有限公司 二、与会计师事务所沟通情况 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 本次业绩预告相关的财务数据为公司财务部门初步测算结果，未经会计师事 务所审计。公司对业绩预告有关事项已与年报审计会计师事务所进行了预沟通， 公司与会计师事务所在本报告期的业绩预告方面不存在分歧。 三、业绩变动原因说明 本次业绩变动的主要原因系公司新拓展的健康消费品及医疗健康业务板块 尚处于市场培育期，相关业务收入尚未形成规模效应，导致固定成本分摊比例较 高，从而对整体利润产生阶段性影响。 报告期内，公司预计非经常性损益对净利润的影响金额约为 1,300-1,600 万 元。 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：预计净利润为负值 | 项目 | | 本报告期 | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏 ...

证券代码：301111 证券简称：粤万年青 公告编号：2026-003 广东万年青制药股份有限公司 关于开立募集资金现金管理专用结算账户及使用部分闲置募 集资金（含超募资金）和自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日 召开第三届董事会第十次会议，并于 2025 年 12 月 31 日召开 2025 年第四次临 时股东会，审议通过了《关于使用部分闲置募集资金（含超募资金）和自有资 金进行现金管理的议案》，同意公司在确保不影响正常运营和募集资金投资项目 建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿元）的闲置募集资金 （含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的自有资金进行现金 管理，上述额度自股东会审议通过之日起 12 个月内有效。在上述额度和期限范 围内，资金可循环滚动使用，并授权公司管理层在额度范围内行使相关决策权、 签署相关合同文件等。具体内容详见公司于 2025 年 12 月 16 日及 2025 年 ...

格隆汇1月14日丨粤万年青(301111.SZ)公布，公司收到合和投资出具的《告知函》,获悉合和投资于2025 年12月3日至2026年1月13日期间，通过集中竞价交易及大宗交易的方式累计减持公司股份3,190,000股， 占公司总股本的比例为1.99375%。本次减持后，合和投资持有公司股份8,010,000股，占公司总股本的 比例为5.00625%。合和投资决定提前终止本次股份减持计划，剩余未减持股份在本次减持计划期限内 不再减持。 ...